Scribd
Upload
7 views4 pages

Preclinical Evaluation of Rituximab

Rituximab is a chimeric monoclonal antibody targeting CD20, a protein expressed on B cells, that was evaluated preclinically for the treatment of B cell lymphomas and other B cell disorders. Preclinical studies showed rituximab bound specifically to CD20, induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and had anti-tumor activity in mouse models of B cell lymphoma without causing significant toxicity. Based on these promising preclinical results, rituximab advanced to clinical trials.

Uploaded by

yogitakadam
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOC, PDF, TXT or read online on Scribd
7 views4 pages

Preclinical Evaluation of Rituximab

Rituximab is a chimeric monoclonal antibody targeting CD20, a protein expressed on B cells, that was evaluated preclinically for the treatment of B cell lymphomas and other B cell disorders. Preclinical studies showed rituximab bound specifically to CD20, induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and had anti-tumor activity in mouse models of B cell lymphoma without causing significant toxicity. Based on these promising preclinical results, rituximab advanced to clinical trials.

Uploaded by

yogitakadam
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOC, PDF, TXT or read online on Scribd

PRECLINICAL EVALUATION OF RITUXIMAB

(Chimeric anti-CD20 monoclonal antibody; Rituxan®or MabThera®)

Disease and target background (max 500 words)

a. Disease definition

b. Disease prevalence

c. Target definition

d. Target history
2. Drug background (max 500 words)

a. Definition of the drug

b. Mechanism of action

c. Drug history

d. Patent status

e. Market share (if available)

3. Drug discovery process this drug went through

a. Target identification (max 200 words)


b. Target validation (max 200 words)

c. Compound screening (max 200 words)

a. Lead identification and optimisation (max 200 words)

b. Preclinical evaluation (DMPK, toxicology, in vitro and in vivo


pharmacology;max 500 words)

c. Clinical evaluation (max 200 words)


4. Summary and conclusions (max 200 words)

You might also like